Introduction {#s1}
============

In colon carcinoma (CC) as for other cancers, the understanding of cellular and molecular mechanisms involved in tumor progression is essential to provide the rationale for novel therapies. According to the 2016 NCCN Panel, CC is the fourth most frequently diagnosed tumor and the second leading cause of death in the USA. Incidence in Italy raised from 27.06% in 1970 to 52.65% in 2010 (Ciatto, [@B13]). Reactivation or alteration of molecular pathways that control cellular differentiation and proliferation play a role in the development and progression of both familiar and sporadic CC (Al-Sohaily et al., [@B2]; Bertrand et al., [@B7]). Numerous studies demonstrated that chemotherapy may be helpful both for primary and for metastatic tumors (Nappi et al., [@B31]). However, the persistence of cases of local recurrence in patients treated with current protocols impels to study the impact of novel pathways active in CC pathogenesis.

Hh pathway plays an important role in tissue development and organogenesis (Jiang and Hui, [@B23]; Rimkus et al., [@B37]). However, in mature organisms, Hh pathway remains selectively active, controlling cell proliferation and differentiation.

Hh ligands are expressed by various stromal and parenchymal tissues and act generally in a paracrine way by binding to the plasma membrane receptor Patched (PTCH1). Upon binding of Hh ligands to PTCH1, the G-protein--coupled receptor, Smoothened (SMO) is activated and promotes nuclear translocation of GLI family of zinc finger transcription factors. GLI activation induces the transcription of Hh target gene products, including ubiquitous genes such as GLI1, PTCH1, and Hh-interacting protein (HIP1) (Benvenuto et al., [@B5]; Rimkus et al., [@B37]). This canonical Hh signaling cascade plays a role in the normal gastrointestinal development, regulating the differentiation of normal intestinal villi and of the adjacent mesenchymal stromal cells. In particular, in the normal adult gastrointestinal tract, induction of the Hh pathway protects the differentiated epithelial cells of the villous surface at the top of the crypts of Lieberkuhn (the structural unit of the normal colon), counteracting the canonical Wnt signaling in the basal cells of the crypt. In the absence of Hh ligand, PTCH1 suppresses the activation of SMO.

Since Hh pathway is involved in the control of proliferation/differentiation status in many tissues, it is not surprising that Hh expression and activity are altered in tumors (Scales and de Sauvage, [@B38]).

Aberrant Hh signaling, which can be achieved by mutational inactivation of PTCH1, aberrant expression of its ligand, constitutive activation of SMO or gene amplification of GLI-associated transcription factors, has been implicated in the initiation and/or maintenance of different cancer types, including basal cell carcinoma (BCC), lung, and brain tumors and rhabdomyosarcoma (Gupta et al., [@B20]).

The involvement of Hh pathway in the pathogenesis of CC and the potential relevance for therapy has been already addressed by different studies. It has been demonstrated that Hh-GLI activity in epithelial tumor cells of CC is essential for tumor growth, recurrence and metastasis, and regulates the behavior of human CC stem cells *in vivo* (Varnat et al., [@B44]). However, a randomized phase II trial using a pharmacological inhibitor of Hh failed to show an incremental benefit respect to standard treatments in a population of previously untreated patients with metastatic CC (Berlin et al., [@B6]). In spite of this, recent research based on *in vitro* and *in vivo* experimental systems, led to controversial results (Gerling et al., [@B19]; Kangwan et al., [@B24]; Lee T. Y. et al., [@B25]; Wang et al., [@B46]).

The aim of the present study was to analyze whether pharmacological inhibition of Hh pathway, and specifically of SMO, impacts epithelial plasticity and invasiveness in different CC cell lines, and to explore the molecular mechanisms involved. Starting from our evidence correlating Hh pathway effectors (i.e., GLI1 and GLI2) with CC patients survival, we first treated CC cell lines with a pharmacological SMO inhibitor, GDC-0449, a small molecule already approved by the US Food and Drug Administration (FDA) for the treatment of advanced basal cell carcinoma (BCC) (Dijkgraaf et al., [@B15]; Takebe et al., [@B42]). In addition, we investigated the effects of SMO-specific genetic silencing as well as 5E1, a Shh-specific Monoclonal Antibody (mAb). Our results show that Hh pathway impacts epithelial/mesenchymal features and invasion capability of CC cell lines.

Materials and methods {#s2}
=====================

Cells
-----

Primary (HCT 116, SW480) and metastatic (SW620) human CC cell lines were grown in DMEM supplemented with 10% FBS (GIBCO® Life Technology, Monza, Italy) and antibiotics. These cellular lines were reported to express detectable levels of SMO and GLI1 (Sun et al., [@B41]; Sénicourt et al., [@B39]; Wang et al., [@B45]). MeT5A cells, a human mesothelium non-tumorigenic cell line were grown in M199 supplemented with 10% FBS (GIBCO® Life Technology, Monza, Italy) and antibiotics.

RNA extraction, reverse transcription (RT), and real-time polymerase chain reaction (RT-qPCR)
---------------------------------------------------------------------------------------------

RNA, extracted from cell cultures with ReliaPrep™ RNA Tissue Miniprep System (Promega, Madison, WI, USA), was reverse transcribed with iScriptTM c-DNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer\'s instructions. cDNAs were amplified by qPCR reaction using GoTaq® qPCR Master Mix (Promega, Madison, WI, USA). The specific primer pairs are listed in Table [1](#T1){ref-type="table"}. Relative amounts, obtained with 2^−ΔCt^ method, were normalized with respect to the housekeeping gene L32. Statistical significance was determined with a *t*-test with GraphPad Prism version 5.0 (La Jolla, CA, USA). Differences were considered significant at *P* \< 0.05 (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).

###### 

List of specific primer pairs for qRT-PCR used in this study.

  ***Gene***     **Oligonucleotide sequence**
  -------------- ------------------------------
  *L32 FW*       GGAGCGACTGCTACGGAAG
  *L32 REV*      GATACTGTCCAAAAGGCTGGAA
  *GLI1 FW*      GACGCCATGTTCAACTCGATG
  *GLI1 REV*     CAGACAGTCCTTCTGTCCCCAC
  *PTCH1 FW*     GAGCAGATTTCCAAGGGGAAGG
  *PTCH1 REV*    ATGAGGAGGCCCACAACCAA
  *HIP1 FW*      AGAACTGCAAAATGTGAGCCAG
  *HIP1 REV*     CTGATCAAGAATACCTGCCCTG
  *MUC5AC FW*    CCATTGCTATTATGCCCTGTGT
  *MUC5AC REV*   TGGTGGACGGACAGTCACT
  *CYC D1 FW*    CCTCTAAGATGAAGGAGACCA
  *CYC D1 REV*   CACTTGAGCTTGTTCACCA
  *P21 FW*       GAGGAGGCGCCATGTCAGAA
  *P21 REV*      AGTCACCCTCCAGTGGTGTC
  *SNAIL1 FW*    CACTATGCCGCGCTCTTTC
  *SNAIL1 REV*   GCTGGAAGGTAAACTCTGGATTAGA
  *CK18 FW*      CTGGAGACCGAGAACCGGA
  *CK18 REV*     TCCGAGCCAGCTCGTCAT
  *SMO FW*       TGAAGGCTGCACGAATGAGG
  *SMO REV*      CTTGGGGTTGTCTGTCCGAA

Antibodies and chemicals
------------------------

Monoclonal antibody against E-cadherin was from BD (Becton-Dickinson Laboratories, Mountain View, CA). Monoclonal antibodies against Snail1 and against GLI1 were from Cell signaling (Danvers, MA). Monoclonal antibody against pan-cytokeratin was from Sigma (St Louis, MO). Polyclonal antibodies against SMO (N-19) and tubulin were from Santa Cruz biotechnology (Dallas, USA). GDC-0449, a Hedgehog/Smoothened pharmacological inhibitor, was a kind gift from Genentech (South San Francisco, CA). 5E1, Shh specific mAb was purchased by Developmental Studies Hybridoma Bank (Iowa City, Iowa, US) (Ericson et al., [@B17]).

siRNA-mediated SMO knockdown
----------------------------

200 × 10^3^ cells were seeded on 12-well plates 24 h prior transfection. Cells were transfected with either 40 pmol ON-TARGETplus SMARTpool against human SMO (Dharmacon Ref\#SO-2600349G) or the same amount of ON-TARGETplus NontargetingPool (Dharmacon Ref\#D-001206-14-05) and 2 μl Lipofectamine® RNAiMAX Reagent from Thermo Fisher Scientific (Waltham, MA USA) in 200 μl Optimem from Gibco (Waltham, MA USA). 1 ml of supplemented medium per well was also added. Forty-eight hours after transfection, knockdown efficiency was determined by RT-PCR and western blot.

Western blotting
----------------

Monolayers of HCT 116 cells were lysed in modified RIPA buffer containing: 50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.1% SDS; 0.25% Nadeoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM PMSF; 1 μg/ml each of aprotinin, leupeptin, and pepstatin; and 25 mM NaF (all from Sigma). Equal amounts of proteins were resolved by SDS-PAGE. Proteins were transferred to nitrocellulose membranes, probed with antibodies and detected as in Battistelli et al. ([@B4]).

### Scratch assay

CC cell lines were pretreated with DMSO or 1 μM GDC-0449 for 24 h in culture medium until reaching 100% confluency. A scratch wound was created on the cell surface using a micropipette tip in low serum (0.5% FBS) culture medium to inhibit cell proliferation. Micrographs were taken at time 0 and 24 h after the scratch. Cell devoid areas at time 0 and 24 h after the scratch were quantified through ImageJ software (NIH, Bethesda, MD, USA). Three independent experiments for each cell line were performed

### 3-Dimensional invasion assay and immunofluorescence

3-dimensional invasion assays were performed as in Strippoli et al. ([@B40]). HCT 116 cells (1.5 × 105) were treated with 1 μM GDC-0449 or vehicle for 12 h and then seeded in triplicate in Ibidi 15-well chambers and allowed to attach for 3 h. 40% matrigel (40 μl) in serum-free medium was laid over the cells. After 1 h, 50 μl full medium containing 20% serum (and GDC-0449 or vehicle) was added and cells incubated for 72 h. Cells were fixed with 4% paraformaldehyde (PFA), permeabilized with 0.25% Triton in PBS, and stained for 12 h with rhodamine-phalloidin (to stain F-actin) and Hoechst (to stain nuclei) in PBS. Confocal images were captured with a Leica SP5 fitted with a 40 × oil objective. Maximum projection images consist of 30 individual images with a z-distance of 120 μm. Imaris image analysis software (Bitplane Scientific Software) was used to create a 3D view of the same cells and to quantify invading cells. Three independent experiments were performed.

Statistical analysis
--------------------

Survival analysis significance was based on Logrank Test. Statistical significance of experiments performed with cell lines was determined with a *t*-test using GraphPad Prism version 5.0 (La Jolla, CA, USA). Differences were considered significant at *P* \< 0.05.

Results {#s3}
=======

GLI altered expression correlates with reduced survival in CC patients
----------------------------------------------------------------------

To determine the clinical relevance of Hh-GLI pathway in CC, we examined the association between increased *GLI* mRNA expression and CC survival by exploring gene expression data microarray from a cohort of 382 CC patients in the cancer genome atlas (TCGA) database (Cerami et al., [@B10]; Gao et al., [@B18]).

Notably, patients with increased *GLI1* expression showed a statistically significant reduction in overall survival (OS) (Figure [1](#F1){ref-type="fig"}) and a trend toward reduced disease-free survival (DFS) (Figure [S1A](#SM1){ref-type="supplementary-material"}). Patients with increased *GLI2* expression showed tendency to reduced survival (Figure [S1B](#SM1){ref-type="supplementary-material"}). These findings support a role for GLI1 and GLI2 in CC pathogenesis, and prompted us to investigate if pharmacological inhibition of Hh pathway could affect the proliferation or the invasive capacity of CC cell lines.

![Kaplan-Meier survival estimate plots for increased *GLI* mRNA expression in CC patients. The survival estimate was analyzed in <http://www.cbioportal.org> (Cerami et al., [@B10]; Gao et al., [@B18]) and is based on Colorectal adenocarcinoma TCGA provisional dataset, which is generated by <http://cancergenome.nih.gov/>. The cases were set to include tumor samples with mRNA data (RNA Seq V2, *n* = 382 patients). The red line shows overall survival estimate for patients with increased *GLI1* expression (11% of the patients) as compared to patients with no alteration (blue line, the rest of the patients). Eight patients were missing in the survival analysis. The threshold for altered expression was set to z-score value = 1.2 The z-score value is used to define the cut-off for patient dichotomization in the TCGA datasets (see <http://www.cbioportal.org/>). The median months survival for the increased *GLI1* patient group and the reference group were 47.04 and 92.67, respectively. Survival analysis significance was based on Logrank Test. *P* \< 0.05 was considered significant.](fphar-08-00956-g0001){#F1}

GDC-0449 limits cellular proliferation of several CC cell lines
---------------------------------------------------------------

We analyzed whether treatment with GDC-0449 affects the expression of Hh pathway specific genes in CC lines. We exposed HCT 116, SW480, primary CC lines, and SW620, a metastatic CC cell line, to GDC-0449 for 24 h at a concentration (1 μM) that is compatible with cellular viability. As shown in Figures [2A--D](#F2){ref-type="fig"}, treatment with GDC-0449 significantly reduced the expression of *GLI1, PTCH1, HIP1, and MUC5AC*, four of the known Hh target genes, thus demonstrating that Hh pathway is constitutively active in all three cell lines. GLI1 protein expression upon treatment with GDC-0449 was shown in Figures [S2A](#SM2){ref-type="supplementary-material"}--[C](#SM2){ref-type="supplementary-material"}. Raw data of the original western blots shown in this study are displayed in Figures [S5](#SM5){ref-type="supplementary-material"}--[S7](#SM7){ref-type="supplementary-material"}.

![Effect of Hh inhibition on Hh pathway-induced genes. HCT 116, SW480 and SW620 were treated with DMSO vehicle (NT) or with 1 μM GDC-0449 for 24 h. Expression of *GLI1* **(A)**, *PTCH1* **(B)**, *HIP1* **(C)**, *MUC5AC* **(D)** was evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 7 experiment for HCT 116 cells, three experiments for SW480 and SW620 cells. Expression of *GLI1, PTCH1, HIP1, MUC5AC* in HCT 116 cells transfected with either control or specific SMO-targeting siRNAs **(E)**. Expression of *GLI1, PTCH1, HIP1, MUC5AC* in HCT 116 cells treated with either isotype-control mAb or 5E1 mAB **(F)**. Bars represent means ± SEM of three experiments. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001.](fphar-08-00956-g0002){#F2}

Similar results were obtained by genetically silencing SMO, and by using 5E1, a mAb specifically binding to Shh (Figures [2E,F](#F2){ref-type="fig"}). The extent of SMO knockdown at mRNA level is shown in Figure [S3A](#SM3){ref-type="supplementary-material"}. Notably, the efficacy of 5E1 mAb, in the absence of exogenous stimulation, suggests the existence of an autocrine loop maintaining Hh pathway constitutively active in these cells.

Conversely in the MeT5A cell line, a non-tumorigenic mesothelium cell line, the same genes were found not responsive to the treatment with GDC-0449, therefore suggesting that these cells do not maintain a constitutively active SMO-GLI pathway (Figure [S3B](#SM3){ref-type="supplementary-material"}).

In order to evaluate the effect of SMO inhibition on cell proliferation, we exposed HCT 116, SW480, SW620, and MeT5A cells, to GDC-0449 for 24--48 h. At the concentration of 1 μM, GDC-0449 significantly inhibited cell proliferation in HCT 116, SW480, and SW620 while causing negligible effect in MeT5A cells (Figures [3A--D](#F3){ref-type="fig"}.) At the molecular level, treatment with GDC-0449 reduced the expression of cell cycle promoters (*Cyclin D1*) while inducing the expression of cell cycle inhibitors (*p21*) in all of the three CC lines analyzed (Figures [3E,F](#F3){ref-type="fig"}). Accordingly, both genetic silencing of *SMO* and treatment with 5EI mAb led to a reduction of *Cyclin D1* (Figure [3G](#F3){ref-type="fig"}), while increasing the expression of *p21* (Figure [3H](#F3){ref-type="fig"}). In contrast, no significative changes in the expression of these genes where detected when MeT5A were treated with GDC-0449 at the same concentrations (Figure [S3C](#SM3){ref-type="supplementary-material"}). These results demonstrate that activation of Hh pathway delivers proliferative signals in CC cell lines.

![Effect of Hh inhibition on cell proliferation. **(A)** HCT 116, **(B)** SW480, **(C)** SW620 or **(D)** MeT5A cells were treated with vehicle (DMSO) or with GDC-0449 (1 μM) for 24--48 h. Cell proliferation was evaluated through microscopic count of living cells. Three independent experiments for each cell line were performed. Expression of *Cyclin D1* **(E)** and *p21* **(F)** was evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 7 experiment for HCT 116 cells, three experiments for SW480 and SW620 cells. **(G)** Expression of *Cyclin D1* mRNA was evaluated in HCT 116 cells transfected with either control or specific *SMO*-targeting siRNAs (left), or in HCT 116 cells treated with either isotype-control mAb or 5E1 mAb (10 μg/ml) (right). **(H)** Expression of *p21* mRNA was evaluated in HCT 116 cells transfected with either control or specific *SMO*-targeting siRNAs (left), or in HCT 116 cells treated with either isotype-control mAb or 5E1 mAb (10 μg/ml) (right). Bars represent means ± SEM of three independent experiments. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01.](fphar-08-00956-g0003){#F3}

GDC-0449 inhibits cell-directed motility and invasion and induces met
---------------------------------------------------------------------

We then analyzed whether GDC-0449 potentially inhibits tumor invasion. In order to analyze the effect of GDC-0449 in controlling cell directed motility, which is relevant for tumor invasion, we performed a scratch assay. Confluent HCT 116 monolayers were pre-treated with GDC-0449 for 24 h, a scratch was performed and the scratch closure was evaluated after 24 h. As shown in Figure [4A](#F4){ref-type="fig"}, treatment with GDC-0449 significantly limited scratch closure.

![Effect of Hh inhibition on cell directed migration and on EMT-MET dynamics. **(A)** HCT 116 cells were treated with vehicle (DMSO) or with GDC-0449 (1 μM) in culture medium supplemented with 0.5% FCS. A scratch was performed and micrographs were taken 24 h after the scratch. Wound closure rate was quantified (right). Three independent experiments were performed. **(B)** HCT 116 cells were pretreated with GDC-0449 for 24 h and then overlaid with a Matrigel matrix. Invasion was monitored over 72 h. Three-dimensional invasion was enhanced by adding 20% FCS to the wells on top of Matrigel. Cells were stained with phalloidin (green) and Hoechst 33342 (cell nuclei, blue). Scale bar: 100 μm. 3 dimensional invasion rate was quantified (right). Three independent experiments were performed. **(C,D)** Effect of GDC-0449 on genes related to EMT-MET dynamics. **(C)** HCT 116, SW480, and SW620 cells were treated with GDC-0449 (1 μM) or DMSO for 24 h. Expression of *Snail1* mRNA was evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 7 experiment for HCT 116 cells, three experiments for SW480 and SW620 cells. **(D)** Expression of Snail1 and E--cadherin in cells treated as above by western blot on total protein lysates of HCT 116 cells treated as stated in the figure. Tubulin was used as a loading control. Three independent experiments were performed. Quantification of E-cadherin and Snail1 protein expression is shown below. **(E)** Expression of *Cytokeratin 18* (CK18) mRNA from total RNA of HCT 116 cells treated as in **(C)**. **(F)** Cytokeratin expression and localization in HCT 116 cells was evaluated through immunofluorescence analysis. Nuclei were stained in blue with Hoechst. Quantification of Cytokeratin mean intensity is shown on the right. Two independent experiments were performed. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01.](fphar-08-00956-g0004){#F4}

Similar results were obtained by using SW480 and SW620 cells (Figures [S4A,B](#SM4){ref-type="supplementary-material"}). By contrast GDC-0449 treatment had no effect on the Hh-irresponsive cell line MeT5A (Figure [S4C](#SM4){ref-type="supplementary-material"}).

Notably, the use of a 3-dimensional invasion assay on Matrigel matrices highlighted also a reduced invasive capacity of GDC-0449-treated HCT 116 cells (Figure [4B](#F4){ref-type="fig"}).

At the molecular level, treatment with GDC-0449 markedly reduced the expression of Snail1, a main driver of EMT and tumor invasion, in all CC cell lines analyzed, while increasing the expression of the typical epithelial marker E-cadherin (Figures [4C,D](#F4){ref-type="fig"}). At the same time, Cytokeratin 18 (CK18) expression was increased both at mRNA and at protein level (Figures [4E,F](#F4){ref-type="fig"}). These results were confirmed by genetic silencing of SMO and by the use of 5E1 mAb (Figures [5A--D](#F5){ref-type="fig"}).

![**(A)** *Snail1* and **(B)** *Cytokeratin 18* expression was evaluated on total RNA by qRT-PCR from HCT 116 cells transfected with either control or specific *SMO*-targeting siRNAs (left), or from cells treated with either isotype-control mAb or 5E1 mAb (10 μg/ml) (right) (*n* = 3). **(C)** Western blot showing expression of SMO, E-cadherin, Snail1 in HCT 116 cells transfected with either control or specific *SMO*-targeting siRNAs. Quantification of SMO, E-cadherin and Snail1 is shown on the left. (*n* = 3). **(D)** Western blot showing the expression of E-cadherin, Snail1 in HCT 116 cells treated with either isotype-control mAb or 5E1 mAb (10 μg/ml). Tubulin was used as loading control. E-cadherin and Snail1 quantifications are shown on the right. Bars represent means ± SEM of three independent experiments.^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01.](fphar-08-00956-g0005){#F5}

These data are in accordance with a data set from CC patients (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}), from the cancer genome atlas (TCGA) database (Cerami et al., [@B10]; Gao et al., [@B18]), where increased expression of Hh pathway genes (GLI1 and SMO) negatively correlates with protein expression of CDH1 (E-cadherin, epithelial marker) and positively correlate with CDH2 (N-Cadherin) and FN (Fibronectin), mesenchymal markers.

###### 

Mean protein expression changes in CC patients with GLI1 mRNA overexpression.

  **Gene**      **Mean protein expression**   **Stdev. of protein expression**   ***p*-Value**          
  ------------- ----------------------------- ---------------------------------- --------------- ------ -------------
  FASN          −0.5                          0.1                                0.59            0.6    0.000001046
  FOXM1         −0.36                         0.02                               0.38            0.56   0.000001847
  CCNB1         −0.77                         0.02                               0.9             0.78   0.000009887
  CCNE1         −0.26                         0.06                               0.36            0.46   0.00001511
  RPS6          −0.45                         0.04                               0.59            0.52   0.00002737
  MSH6          −0.49                         −0.02                              0.58            0.6    0.00004738
  ACACB_PS79    −0.34                         0.02                               0.48            0.46   0.0001271
  ACACA_PS79    −0.34                         0.02                               0.48            0.46   0.0001271
  SLC1A5        −0.63                         −0.04                              0.82            0.62   0.0001453
  CASP7         −0.49                         0.13                               0.82            1.16   0.0001513
  ACACA         −0.43                         0                                  0.61            0.62   0.0002158
  DIRAS3        0.23                          0.06                               0.23            0.33   0.0003006
  FN1           0.75                          0.15                               0.87            0.78   0.0003219
  PEA15         0.28                          0.07                               0.3             0.31   0.0003356
  COL6A1        0.73                          0.08                               1               0.59   0.0004711
  ARID1A        −0.12                         0                                  0.19            0.27   0.0004835
  CDH2          0.15                          0.03                               0.18            0.25   0.0005421
  EIF4E         −0.15                         0.04                               0.29            0.29   0.000731
  CHEK2         −0.29                         0.09                               0.62            0.44   0.0009215
  RPS6KA1       −0.16                         0.09                               0.4             0.43   0.0009856
  CCNE2         −0.07                         0.05                               0.19            0.24   0.001171
  SMAD1         −0.13                         0.02                               0.23            0.23   0.001174
  FOXO3_PS318   0.18                          −0.03                              0.36            0.24   0.001343
  MSH2          −0.07                         0.12                               0.32            0.32   0.001649
  EEF2          −0.23                         0.01                               0.4             0.41   0.001656
  ASNS          −0.13                         0.15                               0.46            0.57   0.001962
  HSPA1A        0.82                          0.23                               1.04            0.86   0.002055
  ITGA2         −0.23                         0.07                               0.52            0.46   0.002136
  PCNA          −0.21                         0.01                               0.4             0.37   0.002343
  CTNNB1        −1.06                         −0.32                              1.34            1.01   0.002551
  TGM2          0.22                          0.06                               0.28            0.31   0.002916
  RB1           −0.06                         0.12                               0.32            0.32   0.003076
  BCL2          0.22                          0.02                               0.35            0.45   0.003119
  ACVRL1        0.3                           0.04                               0.49            0.37   0.00349
  ERBB3         −0.27                         0.05                               0.59            0.61   0.004059
  BAP1          −0.32                         −0.08                              0.46            0.48   0.004078
  RPS6KB1       −0.3                          −0.08                              0.43            0.37   0.004689
  ANXA1         0.34                          0.03                               0.6             0.59   0.005383
  CDH1          −0.93                         −0.3                               1.24            1      0.005527
  CDKN1A        0.2                           0.03                               0.33            0.36   0.00556
  BRD4          −0.42                         −0.11                              0.63            0.5    0.006666
  STK11         0.11                          0.04                               0.14            0.15   0.006734
  SQSTM1        −0.31                         −0.02                              0.59            0.52   0.006856
  EIF4EBP1      −0.13                         0.04                               0.35            0.34   0.007095
  BAK1          0.12                          0.04                               0.17            0.21   0.007894
  NRAS          0.17                          0.08                               0.19            0.23   0.008201
  PGR           0.23                          0.11                               0.24            0.31   0.008854
  CDK1_PY15     −0.23                         0                                  0.48            0.31   0.008911
  MRE11A        0.15                          0.04                               0.23            0.17   0.009363
  AR            0.18                          0.06                               0.27            0.26   0.0104
  WWTR1         0.13                          0.01                               0.27            0.27   0.0138
  G6PD          0.15                          0.04                               0.24            0.31   0.0142
  TP53BP1       −0.4                          −0.05                              0.78            0.72   0.0145
  BECN1         0.13                          0.02                               0.24            0.22   0.015
  RBM15         −0.54                         −0.11                              0.98            0.62   0.0159
  TFRC          −0.35                         0.02                               0.84            0.85   0.0159
  EIF4G1        −0.66                         −0.27                              0.88            0.93   0.0181
  ESR1          0.19                          0.07                               0.28            0.36   0.0188
  CLDN7         −0.63                         −0.07                              1.32            1.04   0.019
  XRCC5         −0.27                         −0.02                              0.59            0.5    0.0194
  TSC2          −0.32                         −0.06                              0.62            0.49   0.023
  GAPDH         −0.39                         −0.06                              0.81            0.74   0.0289
  MS4A1         0.12                          0.04                               0.22            0.18   0.029
  KIT           0.28                          −0.07                              0.88            0.9    0.0297
  FOXO3         0.13                          0.05                               0.19            0.24   0.03
  GSK3B         −0.06                         0.05                               0.28            0.24   0.0306
  GSK3A         −0.06                         0.05                               0.28            0.24   0.0306
  CCND1         0.07                          −0.01                              0.21            0.23   0.0366
  CDKN1B        0.21                          0.09                               0.32            0.34   0.0376
  MAPK8_PT183   0.27                          0.02                               0.68            0.39   0.0383
  RAB11B        0.14                          0.03                               0.29            0.24   0.041
  RAB11A        0.14                          0.03                               0.29            0.24   0.041
  CASP8         −0.04                         0.14                               0.45            0.79   0.0414
  YAP1          0.29                          0.14                               0.42            0.37   0.0445

*Data was extracted from cBioPortal, Colorectal Adenocarcinoma (TCGA, Provisional), n(patients) = 382, z-score threshold = 1.2. The patient set was the same as in the survival analysis (see Figure [1](#F1){ref-type="fig"}). Protein measurements are based on antibody arrays (RPPA = Reverse Phase Protein Array), and the table shows only those proteins with significant p-value (p \< 0.05). The z-score threshold used was the same as in the survival analysis (see Figure [1](#F1){ref-type="fig"}), where z-score 1.2 resulted in the best separation of patient groups into Gli1 mRNA overexpressing and non-overexpressing patients*.

###### 

Mean protein expression changes in CC patients with SMO mRNA overexpression.

  **Gene**      **Mean protein expression**   **Stdev. of protein expression**   ***p*-Value**          
  ------------- ----------------------------- ---------------------------------- --------------- ------ -----------
  RPS6KA1       −0.13                         0.1                                0.32            0.44   0.0001553
  FN1           0.57                          0.16                               0.67            0.82   0.0005204
  GAPDH         −0.42                         −0.05                              0.62            0.76   0.0006319
  CLDN7         −0.61                         −0.06                              1.08            1.07   0.002821
  CASP7         −0.36                         0.13                               0.98            1.15   0.003758
  PTEN          −0.12                         −0.03                              0.21            0.22   0.006982
  PEA15         0.21                          0.08                               0.29            0.32   0.008334
  YAP1          0.32                          0.13                               0.43            0.36   0.0113
  SYK           −0.21                         0.03                               0.59            0.54   0.0138
  SLC1A5        −0.36                         −0.07                              0.76            0.65   0.0142
  TFRC          −0.32                         0.03                               0.87            0.84   0.0172
  VHL           −0.59                         −0.18                              1.04            1.21   0.0193
  LCK           −0.06                         0.09                               0.37            0.47   0.0201
  ERBB3         −0.17                         0.04                               0.51            0.62   0.0216
  FOXO3_PS318   0.09                          −0.02                              0.29            0.26   0.0222
  CTNNB1        −0.78                         −0.34                              1.15            1.05   0.0223
  CDKN1B        0.2                           0.08                               0.32            0.34   0.0281
  PECAM1        0.15                          0.04                               0.29            0.27   0.0282
  MRE11A        0.11                          0.04                               0.2             0.17   0.0287
  EEF2          −0.14                         0                                  0.38            0.42   0.0304
  RB1           0                             0.11                               0.3             0.33   0.0304
  TSC2          −0.25                         −0.07                              0.52            0.51   0.0308
  INPP4B        −0.17                         0.01                               0.5             0.63   0.0365
  RBM15         −0.4                          −0.12                              0.82            0.65   0.0375
  AR            0.16                          0.06                               0.31            0.25   0.0381
  EGFR          −0.13                         −0.05                              0.21            0.25   0.0393
  WWTR1         0.09                          0.01                               0.21            0.28   0.04
  CDH1          −0.69                         −0.32                              1.11            1.03   0.0401
  CDH2          0.1                           0.03                               0.2             0.25   0.0421
  SMAD4         0.06                          0                                  0.19            0.22   0.0448
  SQSTM1        −0.2                          −0.03                              0.52            0.54   0.0451

*Data was extracted from cBioPortal, Colorectal Adenocarcinoma (TCGA, Provisional), n(patients) = 382, z-score threshold = 1.2. Protein measurements are based on antibody arrays (RPPA = Reverse Phase Protein Array), and the table shows only those proteins with significant p-value (p \< 0.05). The z-score threshold 1.2 was selected based on optimal separation of patient groups into SMO mRNA overexpressing and non-overexpressing groups*.

Overall, these results demonstrate that in primary and metastatic CC cell lines, the functional blockade of autocrine Hh pathway leads to a reduction of cellular growth and invasion through a reacquisition of epithelial-like features. These results may be helpful to more completely understand the complex biology of CC in light of future therapeutic strategies.

Discussion {#s4}
==========

The involvement of Hh in CC tumorigenesis is presently object of controversy. CC has a complex pathogenesis; during its progression, alterations of multiple genes and pathways are required. The observation that Hh pathway is tightly connected with other pathways that are often abnormally activated in CC, such as Wnt/β-catenin or Ras, strongly suggests its involvement in the multistep process of CC pathogenesis (Brechbiel et al., [@B9]). In fact, recent evidence indicates that Hh signaling may act in CC in autocrine, paracrine or cancer stem cell fashion (Scales and de Sauvage, [@B38]).

Notably, RNA Seq analysis in 382 patients highlighted a significative correlation between GLI1 increased expression and reduced survival in CC patients. These data support the results obtained by other studies (Xu et al., [@B48]), and prompted us to overcome the correlative analysis in pinpointing a mechanism; this attempt implied to inhibit Hh pathway in CC cell lines.

We first evaluated the effect of GDC-0449, a specific SMO inhibitor, on Hh signaling in three primary and metastatic CC cell lines. In all cells analyzed, treatment with GDC-0449 significantly reduced the expression of four known target genes (*GLI1, PTCH1, HIP1, MUC5AC)*, this implying a constitutive activation of Hh pathway. The activity of Hh pathway in CC cell lines has been already analyzed in other studies, with controversial results (Douard et al., [@B16]; Chatel et al., [@B11]; Alinger et al., [@B1]).

The observed discrepancies with some of these studies may be explained by the different cell lines analyzed (Alinger et al., [@B1]) or by the usage of semi-quantitative techniques (Chatel et al., [@B11]).

In our experimental system, treatment of all three lines with GDC-0449 also significantly reduced cell proliferation, whereas there was no effect in a not-responsive cell line used as a negative control.

At the molecular level, cell cycle inducers (Cyclin D1) were decreased, whereas cell cycle blockers (p21) were increased. Therefore, the use of GDC-0449 directly impacts cellular proliferation and potentially tumor growth. These results were confirmed by performing SMO genetic silencing and by using a 5E1 Shh-specific inhibitory mAb. The effect observed using 5E1 presupposes the existence of an autocrine activatory loop involving Shh-SMO-dependent canonical pathway activation. A previous report analyzing loss-of-function mutation in PTCH1 suggested a role of autocrine Hh signaling in colorectal tumorigenesis (Chung and Bunz, [@B12]). The autocrine loop observed by us in CC cell lines may complement other studies supporting a model in which paracrine Hh ligands released by CC cells take a role in instructing the stromal components of the tumor (Yauch et al., [@B49]).

Our results emphasize the role of canonical Hh signaling in CC cell lines, although we do not exclude that other pathways may play a role. Indeed, besides the canonical Hh-PTCH1-SMO-driven signals, ligand-independent pathways have been demonstrated (Merchant et al., [@B30]; Amakye et al., [@B3]). For instance, in tumors, GLI transcription may be decoupled from upstream Shh--PTCH1--SMO signaling being regulated by TGF-β and KRAS (Nolan-Stevaux et al., [@B32]).

Treatment with GDC-0449 also led to reduced cellular motility in both a 2D and a 3D migration assays. These functional data correlated with an increased expression of epithelial markers (E-cadherin, Cytokeratin-18) and with a significant downregulation of Snail1, a main effector of TGF-β pathway. With respect to cellular motility and Snail1 expression, our results appear equally provocative in the light of the fact that in several circumstances TGF-β facilitates tumor invasiveness through induction of epithelial-mesenchymal transition (EMT). EMT is a complex phenotypic conversion of epithelial cells leading to the acquisition of a highly motile phenotype and other mesenchymal traits, and is a key mechanism by which pre-malignant epithelial cells acquire a highly invasive phenotype that leads to metastatic spreading. The evidence of EMT in CC *in vivo* was firstly demonstrated by Brabletz (Brabletz et al., [@B8]). Subsequently, genomics studies identified EMT as a major program in CC (Loboda et al., [@B28]). Moreover, expression of EMT-related genes correlated with poorer survival in CC, but not in other cancers (Tan et al., [@B43]).

Cell migration and invasiveness are driven by actin cytoskeleton dynamic polarization, which is controlled by the members of the Rho GTPase superfamily Rho, Rac, and Cdc42 (Ridley, [@B36]). At the same time, EMT dynamics, as well as the acquisition of stem-like phenotypes are characterized by selective activation of Rho GTPases (Yoon et al., [@B50]). Interestingly, recent studies link Hh pathway to Rho GTPases activation, providing potential molecular mechanisms for our observations (Peng et al., [@B34]).

Hh pathway has been shown to intersect and cooperate with other pathways by regulating the differentiation/proliferation status of the tissue. In the intestinal mucosa, Bone Morphogenetic Protein (BMP) and Hh pathways are preferentially activated in differentiated layers, whereas Notch and WNT pathways are activated in the basal cells of the crypt (Bertrand et al., [@B7]). Hh controls the expression of the Notch ligand Jagged2. Moreover, cross talks between TGF-β-induced pathways and Hh have been demonstrated (Perrot et al., [@B35]). There is evidence of an interplay between Hh and TGF-β pathways in both normal and malignant tissues. In particular, TGF-β may induce GLI1 expression in a GLI2-dependent manner independently from SMO in breast cancer (Hu et al., [@B22]). Furthermore, pharmacologic blockade of TGF-β signaling leads to a reduction of GLI1 expression in cyclopamine-resistant pancreatic adenocarcinoma (Dennler et al., [@B14]).

We hypothesize that in our cells Snail1 downregulation, mediated by Hh-pathway inhibition, contributes to the stabilization of an epithelial phenotype (underlined by the increase in E-cadherin and Cytokeratin 18 expression). Besides the well-known effect on tumor invasion, Snail1 downregulation may be effective in limiting chemoresistance, as recently demonstrated in CC (Lee T. Y. et al., [@B25]). Accordingly, Hh pathway inhibition by GDC-0449 was demonstrated to reduce the expression of a mesenchymal marker and to restore sensitivity to 5-fluorouracil in a 5-fluorouracil-resistant CC cell line (Liu et al., [@B27]).

While the role of Hh pathway in EMT induction in CC has already been demonstrated by Ruiz i Altaba and other groups (Varnat et al., [@B44]; Wang et al., [@B47]; Liu et al., [@B27]), our study firstly described the maintenance of an invasive "EMT like state" by an autocrine secretion of Hh ligands in CC cell lines. This cellular mechanism may play a role in promoting cellular invasion and metastatic spreading of CC to the liver, consistently with our previous findings on tumor-stroma interactions in liver neoplasms (Magistri et al., [@B29]). The impact of Hh pathway on CC tumorigenesis has been recently questioned in mouse models (Gerling et al., [@B19]; Lee J. J. et al., [@B26]). Using different experimental systems such as the AOM/DSS model of colitis-associated CC, it was demonstrated that Hh signaling is downregulated in CC, and that Hh pathway inhibition may intensify colon inflammation (colitis) in mice, thus promoting tumorigenesis.

Conversely, other recent studies linked the same pathway activation to pro-tumor effects and to the acquisition of a cancer stem-like behavior (Kangwan et al., [@B24]; Wang et al., [@B46]).

Finally, it has been demonstrated that Hh active pathway may hamper tumor immunosurveillance (for example downregulating MHC1 expression in epithelial tumor cells), inhibiting the immune response against the tumor (Otsuka et al., [@B33]; Hanna and Shevde, [@B21]). Therefore, the interpretation of *in vivo* models is so far extremely challenging.

In conclusion, our *in vitro* study established a causal link between constitutive Hh activity and the acquisition of pro-invasive, mesenchymal-like properties in CC cell lines.

When looking for a possible translational relevance of these discoveries, one may hypothesize that subsets of colorectal tumors endowed with abnormal Hh signaling due to mutations, such as a recently reported PTCH1 loss-of-function mutation (Chung and Bunz, [@B12]), that may not have been represented in the cohorts previously treated with Hh inhibitors (Berlin et al., [@B6]), may benefit from drugs inhibiting Hh activity such as GDC-0449.
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